ALK and non-small cell lung carcinoma: The anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) who harbor ALK gene rearrangements.